EUCTR2021-005861-41-PL进行中（未招募）1 期
A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE) - Phase 2 MK-2140 + R-CHP Combination in 1L DLBC
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically confirmed diagnosis of DLBCL, by prior biopsy, according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues, which includes but is not limited to: DLBCL, NOS germinal center B-cell type, or activated B-cell type; DLBCL leg-type; EBV+ DLBCL, NOS; and T cell histiocytic-rich DLBCL. DLBCL with overexpression of MYC, BCL2, and/or BCL6 proteins without rearrangement are also classified as DLBCL. DLBCL (HGBL) with MYC, BCL2, and/or BCL6 rearrangement will also be included.
- •Sites are required to collect DLBCL classification of BCL2, BCL6, MYC, ABC, and GCB status.
- •Sites should preform test locally and when not available, will be done centrally. The results are not required prior to C1D1.
- •2. Has PET-positive disease verified by BICR at Screening, defined as 4-5 on the Lugano 5-point scale.
- •3. Has received no prior treatment for their DLBCL.
- •4. Is assigned male or female sex at birth or an individual of any sex or gender = 18 years old at the time of providing documented
- •informed consent.
- •5. If capable of producing sperm, the participant, agrees to the following during the intervention period and for at least the time needed to
- •eliminate study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention is as follows:
- •- Zilovertamab vedotin: 110 days
- •- Cyclophosphamide: 90 days
- •- Doxorubicin: 90 days
- •- Rituximab or rituximab biosimilar (Truxima): no contraception needed
- •Refrains from donating sperm
- •PLUS either:
- •Abstains from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent
- •Uses contraception unless confirmed to be azoospermic as below:
- •- Uses a penile/external condom when having penile-vaginal intercourse with nonparticipant of childbearing potential who is not currently pregnant. PLUS partner use of an additional contraceptive method, as a condom may break or leak.
- •- Contraceptive use by participants capable of producing sperm should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions are more stringent than the requirements above, the local label requirements are to be followed.
- •6. A participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Not a POCBP
- •POCBP and:
- •- Uses a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from penile-vaginal intercourse as their preferred and usual lifestyle, as described in Appendix 5 during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention and agrees not to donate eggs to others or freeze/store eggs during this
- •period for the purpose of reproduction. The length of time required to continue contraception for each study intervention is as follows:
- •. Zilovertamab vedotin: 50 days
- •. Cyclophosphamide: 180 days
- •. Doxorubicin: 180 days
- •. Rituximab or rituximab biosimilar (Truxima): 365 days
- •The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study intervention. Contraceptive use by POCBPs should be consisten
排除标准
- •1. Has a history of transformation of indolent disease to DLBCL.
- •2. Has received solid organ transplant at any time.
- •3. Has received a diagnosis of PMBCL.
- •4. Has clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class =II), or serious cardiac arrhythmia requiring medication.
- •5. Has pericardial effusion or clinically significant pleural effusion.
- •6. Has ongoing Grade >1 peripheral neuropathy.
- •7. Has a demyelinating form of Charcot-Marie-Tooth disease.
- •8. History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
- •9. Has contraindication to any of the study intervention components.
- •10. Has received prior radiotherapy within 28 days of start of study intervention. Participants must have recovered from all radiation-related toxicities.
- •11. Has ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent). Prednisone equivalent dosing must have been stable for at least 28 days prior to C1D1.
- •12. Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
- •13. Has received a strong inhibitor or inducer of CYP3A4 (including itraconazole, ketoconazole, posaconazole, or voriconazole) within 7 days prior to C1D1 or expected requirement for chronic use of a strong CYP3A4 inhibitor until < 30 days after the last dose (see Section 6.5.2).
- •14. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 28 days before the first dose of study intervention.
- •15. Has known active CNS lymphoma. Participants with prior CNS involvement are eligible if their CNS disease is in radiographic, cytological (for cerebrospinal fluid disease), and clinical remission.
- •16. Has an active infection requiring systemic therapy.
- •17. Has a known history of HIV infection.
- •18. Has a known active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
- •19. Has a known active hepatitis B infection defined as positive HBsAg and negative HBcAb or detectable HBV DNA by PCR testing.
- •20. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- •21. Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study.
研究者
相似试验
招募中
1 期
A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: LLTClassification code: 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) Class: 10029104CTIS2022-501380-40-00Merck Sharp & Dohme LLC50
进行中（未招募）
1 期
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma (RRMM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2019-004793-26-DEHarpoon Therapeutics, Inc.114
尚未招募
1 期
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose ExpansionStudy of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patientswith Relapsed/Refractory Multiple MyelomaMultyple Myeloma C90.0C90.0Multiple myelomaDRKS00023656Harpoon Therapeutics, Inc.70
招募中
1 期
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma2024-515582-33-00Harpoon Therapeutics Inc.10
未知
2 期
A Phase 2, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safetyand Tolerability of Intravenous Dose of MEDI-546, a Human Monoclonal Antibody Directed Against Type I Interferon Receptor (IFNAR), in Japanese Subjects With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusJPRN-jRCT2080221785AstraZeneca